NCT03343912View on ClinicalTrials.gov

Estriol and Trimegestone Dose-response Trial With Single Dose Application of Vaginal Rings

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 10, 2017

Primary Completion Date

January 12, 2018

Study Completion Date

February 15, 2018

Conditions
Pregnancy
Interventions
DRUG

Estriol 0.400 mg/day and Trimegestone 0.06 mg/day

Vaginal ring with a nominal delivery rate of 0.400 mg/d estriol (E3) and 0.06 mg/d trimegestone (TMG), vaginal application

DRUG

Estriol 0.300 mg/day and Trimegestone 0.12 mg/day

Vaginal ring with a nominal delivery rate of 0.300 mg/d estriol (E3) and 0.12 mg/d trimegestone (TMG), vaginal application

DRUG

Estriol 0.200 mg/day and Trimegestone 0.18 mg/day

Vaginal ring with a nominal delivery rate of 0.200 mg/d estriol (E3) and 0.18 mg/d trimegestone (TMG), vaginal application

Trial Locations (1)

Unknown

Galeno Desenvolvimento de Pesquisas Clinicas Ltda. - ME, Campinas

All Listed Sponsors
collaborator

SocraTec R&D GmbH

OTHER

lead

Galeno Desenvolvimento de Pesquisas Clínicas

OTHER_GOV

NCT03343912 - Estriol and Trimegestone Dose-response Trial With Single Dose Application of Vaginal Rings | Biotech Hunter | Biotech Hunter